Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.

Verastem Inc.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Verastem (VSTM) and Agilent (A) with bullish sentime...

Wall Street Analysts Are Bullish on Top Healthcare Picks

The latest announcement is out from Verastem ( ($VSTM) ). At its annual meeting of stockholders held on May 21, 2026, in Needham, Massachusetts, Ve...

Verastem Shareholders Back Board, Executive Pay and Plans

H.C. Wainwright analyst Andres Y. Maldonado maintained a Buy rating on Verastem today and set a price target of $18.00. Y. Maldonado covers the Hea...

H.C. Wainwright Sticks to Their Buy Rating for Verastem (VSTM)

High‑risk, high‑reward stocks are companies whose share prices can witness large swings, either up or down, as their future is uncertain. However, ...

3 High-Risk, High-Reward Stocks to Buy Now for Explosive Upside, According to Analysts – 5/22/26

Verastem received a Buy rating and a $16.00 price target from B. Riley Securities analyst today. In a report released on May 13, Mizuho Securities ...

Verastem (VSTM) Receives a Buy from B. Riley Securities

Verastem Inc (($VSTM)) has held its Q1 earnings call. Read on for the main highlights of the call. Verastem Inc’s latest earnings call struck a cau...

Verastem Inc Earnings Call Highlights Growth And Risk

In a report released today, Andres Y. Maldonado from H.C. Wainwright reiterated a Buy rating on Verastem, with a price target of $18.00. Y. Maldona...

Current Quarter	$-0.46	Next Quarter	$-0.43
Current Year	$-1.57	Next Year	$-0.67
QoQ Growth	+6.5%	YoY Growth	+57.3%
3Y EPS CAGR	+12.8%	Target Price	$16.00
Consensus	Buy	Upside	+273.0%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	VSTM	$4.29	+0.94%	1.69M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	VSTM	$4.29	+0.9%	1.69M
3
4
5
6

VSTM

VSTM

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Verastem Inc. Data in Excel

Get Verastem Inc. Data in Excel